See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $283B | 4.4x | 9.8x | |
| $192B | 3.1x | 7.7x | |
| $129B | 2.5x | 8.3x | |
| $114B | 2.7x | 7.9x | |
| $66.8B | 4.2x | 12.6x | |
| $52.9B | 6.4x | 21.5x | |
| $8.5B | n/a | n/a | |
| $8.5B | 5.0x | -64.9x | |
| $8.3B | 2.7x | -6.9x | |
| $7.7B | 8.1x | 26.7x | |
| $6.5B | 54664.0x | n/a | |
| $6.0B | 2.9x | -1.9x | |
| $4.9B | n/a | n/a | |
| $4.5B | 10.5x | 32.1x | |
| $3.5B | 5.2x | 14.3x | |
| $3.4B | 10.8x | 67.3x | |
| $2.6B | 6.3x | 20.5x | |
| $2.6B | 7.2x | 26.0x | |
| $2.5B | n/a | n/a | |
| $2.4B | 10.2x | -6.4x | |
| $2.4B | 5.8x | -76.9x | |
| $2.4B | 23.3x | n/a | |
| $2.0B | 8.7x | -75.2x | |
| $1.8B | 1.9x | 5.2x | |
| $1.8B | 9.2x | 29.4x | |
| $1.8B | 11.0x | 12.1x | |
| $1.6B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.4B | 180.9x | -6.6x | |
| $1.3B | 7.2x | 19.5x | |
| $1.3B | 7.4x | 25.0x | |
| $1.2B | 8.0x | 13.2x | |
| $1.2B | 376.8x | -4.7x | |
| $1.2B | 24.0x | -8.0x | |
| $1.1B | 438.0x | -7.8x | |
| $1.1B | 34.2x | -30.7x | |
| $981M | 3.0x | 36.2x | |
| $932M | 4.8x | -26.6x | |
| $857M | 3.6x | 11.7x | |
| $856M | 5.5x | 10.8x | |
| $813M | 4.0x | -19.6x | |
| $811M | 14.1x | -4.2x | |
| $791M | 6.5x | -8.2x | |
| $757M | 9.0x | -37.4x | |
| $749M | 9214.4x | n/a | |
| $721M | 3.9x | n/a | |
| $618M | 0.6x | 1.9x | |
| $613M | n/a | n/a | |
| $577M | 6.5x | -76.7x | |
| $563M | 11.6x | -8.4x | |
| $556M | n/a | n/a | |
| $542M | 491.5x | -1.7x | |
| $532M | 182.2x | -27.1x | |
| $520M | n/a | n/a | |
| $485M | 38.0x | -0.9x | |
| $464M | n/a | -7.4x | |
| $462M | n/a | n/a | |
| $415M | 1.9x | n/a | |
| $378M | 19.6x | -1318.8x | |
| $371M | 74.8x | n/a | |
| $328M | 1.8x | 7.6x | |
| $308M | n/a | n/a | |
| $285M | 1.4x | 7.1x | |
| $284M | 4211746.3x | -10.7x | |
| $238M | 10469.4x | -1.2x | |
| $223M | 21.1x | -5.9x | |
| $198M | 1.4x | n/a | |
| $194M | 260892.3x | -7.8x | |
| $174M | n/a | -3.9x | |
| $171M | n/a | -1.0x | |
| $166M | 21.4x | n/a | |
| $152M | n/a | n/a | |
| $144M | 38953.9x | -0.7x | |
| $137M | n/a | n/a | |
| $134M | 2.5x | 14.6x | |
| $134M | n/a | n/a | |
| $130M | n/a | -5.1x | |
| $129M | 39.7x | -6.9x | |
| $128M | n/a | n/a | |
| $123M | n/a | n/a | |
| $123M | n/a | n/a | |
| $122M | n/a | n/a | |
| $112M | n/a | n/a | |
| $111M | n/a | n/a | |
| $110M | 0.9x | 3.7x | |
| $105M | 18.5x | n/a | |
| $105M | n/a | n/a | |
| $102M | n/a | -4.2x | |
| $93.9M | 935.1x | n/a | |
| $93.0M | n/a | -0.5x | |
| $87.6M | 711.4x | n/a | |
| $86.5M | n/a | n/a | |
| $77.7M | n/a | n/a | |
| $71.3M | n/a | n/a | |
| $66.8M | 12.4x | n/a | |
| $65.8M | 7.2x | n/a | |
| $61.7M | 0.9x | -0.2x | |
| $60.0M | 20.0x | -1.6x | |
| $50.7M | 31.2x | -1.0x | |
| $45.2M | n/a | n/a | |
| $43.9M | 28.9x | -1.2x | |
| $41.7M | n/a | -0.5x | |
| $40.8M | n/a | n/a | |
| $40.2M | n/a | n/a | |
| $37.8M | 4.6x | n/a | |
| $35.9M | n/a | -1.1x | |
| $27.7M | n/a | n/a | |
| $24.3M | n/a | -0.2x | |
| $23.2M | n/a | n/a | |
| $21.7M | n/a | n/a | |
| $19.0M | 106.3x | n/a | |
| $17.2M | 369.0x | n/a | |
| $16.9M | n/a | n/a | |
| $11.0M | 4.3x | n/a | |
| $10.6M | 4.0x | n/a | |
| $8.4M | 4.6x | -0.3x | |
| $6.8M | 0.1x | -0.0x | |
| $4.9M | 2.2x | n/a | |
| $4.4M | n/a | n/a | |
| $4.3M | 5.6x | -0.3x | |
| $2.8M | 0.8x | -0.2x | |
| $1.2M | 0.2x | n/a | |
| -$9.3M | -1.3x | 0.1x | |
| -$12.2M | -1.2x | n/a | |
| -$15.8M | -0.1x | n/a | |
| -$20.3M | n/a | 0.2x | |
| -$23.2M | -990.6x | n/a | |
| -$26.4M | -2.7x | 0.2x | |
| -$31.7M | -22.7x | n/a | |
| -$57.1M | -1.5x | n/a | |
| -$75.7M | n/a | n/a | |
| -$93.2M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies